WO2010117199A3 - 코엔자임 q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물 - Google Patents

코엔자임 q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물 Download PDF

Info

Publication number
WO2010117199A3
WO2010117199A3 PCT/KR2010/002112 KR2010002112W WO2010117199A3 WO 2010117199 A3 WO2010117199 A3 WO 2010117199A3 KR 2010002112 W KR2010002112 W KR 2010002112W WO 2010117199 A3 WO2010117199 A3 WO 2010117199A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
coenzyme
preparation
composition containing
proteins
Prior art date
Application number
PCT/KR2010/002112
Other languages
English (en)
French (fr)
Other versions
WO2010117199A2 (ko
Inventor
정봉현
한정현
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to JP2012504607A priority Critical patent/JP5690809B2/ja
Priority to CN201080020168.9A priority patent/CN102438606B/zh
Priority to EP10761860.5A priority patent/EP2417970B1/en
Priority to US13/263,296 priority patent/US8785598B2/en
Publication of WO2010117199A2 publication Critical patent/WO2010117199A2/ko
Publication of WO2010117199A3 publication Critical patent/WO2010117199A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B33/00—After-treatment of single crystals or homogeneous polycrystalline material with defined structure
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic System or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
    • H01L21/302—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to change their surface-physical characteristics or shape, e.g. etching, polishing, cutting
    • H01L21/306—Chemical or electrical treatment, e.g. electrolytic etching
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Abstract

본 발명은 코엔자임 Q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물에 관한 것이다. 본 발명에 따르면, 코엔자임 Q10을 수혼화성 유기용매만을 단독으로 사용하여 용해시키고, 낮은 에너지 조건인 단순 교반에 의해 쉽게 나노화 및 가용화시킬 수 있으며, 아미노산 또는 단백질에 의해 분산 안정화시킬 수 있다. 코엔자임 Q10이 나노 크기를 갖고 가용화됨에 따라 체내 흡수율이 증가하며, 나노입자와 함께 아미노산 및 단백질을 동시에 전달할 수 있는바, 코엔자임 Q10 나노입자를 포함하는 식품, 화장품, 의약에의 효과적인 활용이 가능하다.
PCT/KR2010/002112 2009-04-06 2010-04-06 코엔자임 q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물 WO2010117199A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012504607A JP5690809B2 (ja) 2009-04-06 2010-04-06 コエンザイムｑ１０ナノ粒子、その製造方法及び上記ナノ粒子を含む組成物
CN201080020168.9A CN102438606B (zh) 2009-04-06 2010-04-06 辅酶q10纳米颗粒、其制备方法和包含所述纳米颗粒的组合物
EP10761860.5A EP2417970B1 (en) 2009-04-06 2010-04-06 Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles
US13/263,296 US8785598B2 (en) 2009-04-06 2010-04-06 Coenzyme Q10 nanoparticles, preparation method thereof and composition containing said nanoparticles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0029620 2009-04-06
KR1020090029620A KR101066197B1 (ko) 2009-04-06 2009-04-06 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물

Publications (2)

Publication Number Publication Date
WO2010117199A2 WO2010117199A2 (ko) 2010-10-14
WO2010117199A3 true WO2010117199A3 (ko) 2011-03-03

Family

ID=42936712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/002112 WO2010117199A2 (ko) 2009-04-06 2010-04-06 코엔자임 q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물

Country Status (6)

Country Link
US (1) US8785598B2 (ko)
EP (1) EP2417970B1 (ko)
JP (1) JP5690809B2 (ko)
KR (1) KR101066197B1 (ko)
CN (1) CN102438606B (ko)
WO (1) WO2010117199A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201501872XA (en) 2010-03-12 2015-05-28 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
PE20180414A1 (es) 2011-06-17 2018-03-01 Berg Llc Composiciones farmaceuticas inhalables
CN102397242A (zh) * 2011-09-02 2012-04-04 河南康倍得药业有限公司北京技术开发中心 含辅酶q10的水凝胶及由该水凝胶制成的巴布剂
MX2017014197A (es) * 2015-05-08 2018-08-15 Spectral Platforms Inc Complejos no covalentes basados en albumina y metodos de uso de los mismos.
CN105708806B (zh) * 2016-02-02 2018-05-04 扬州大学 一种制备易水分散的辅酶q10纳米颗粒粉末制剂的方法
EP3830066B1 (en) 2018-08-03 2023-10-25 Center for Intelligent Research in Crystal Engineering, S.L. Cocrystals of ubiquinone and compositions comprising them
EP4019122A4 (en) * 2019-10-16 2023-04-26 Nano Cube Japan Co., Ltd. METHOD FOR MAKING AN ULTRAFINE PARTICLE DISPERSION OF WEAKLY SOLUBLE SUBSTANCE
CN112056560A (zh) * 2020-09-18 2020-12-11 烟台硕人生物科技有限公司 一种辅酶q10和褐藻寡糖氧化复合颗粒的制备方法
CN112370442B (zh) * 2020-12-15 2022-03-01 浙江工业大学 一种辅酶q10药物递送系统及其制备方法
CN112972272A (zh) * 2021-03-11 2021-06-18 湖南御家化妆品制造有限公司 一种负载艾地苯醌的纳米微球及其制备方法、化妆品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004203812A (ja) * 2002-12-26 2004-07-22 Kanebo Ltd 経口組成物及びそれを有効成分とする美白剤
JP2004242509A (ja) * 2003-02-10 2004-09-02 Nisshin Pharma Inc コエンザイムｑ１０およびアミノ酸類を含有する食品
EP1591020A1 (en) * 2003-01-17 2005-11-02 Taiyo Kagaku Co., Ltd. Compositions containing coenzyme q10
US20070053985A1 (en) * 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025918A (ja) 1983-07-25 1985-02-08 Ajinomoto Co Inc 脂溶性薬物含有水性液
JPS60199814A (ja) 1984-03-24 1985-10-09 Taisho Pharmaceut Co Ltd ユビデカレノン脂肪乳剤
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
DE9100312U1 (ko) 1991-01-11 1991-04-04 Rahmede Schraubenfabrik Gmbh & Co Kg, 5880 Luedenscheid, De
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
CA2294981C (en) 1997-06-27 2012-04-03 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
KR100463167B1 (ko) 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
JP3549197B2 (ja) * 2001-08-10 2004-08-04 日清ファルマ株式会社 ユビキノン含有製剤
JP4429590B2 (ja) * 2002-02-08 2010-03-10 株式会社協和ウェルネス ユビキノン含有水可溶性組成物
WO2003072118A1 (de) * 2002-02-28 2003-09-04 Gerold Lukowski Mikro-/nanopartikel aus lipidhaltigen marinen organismen für pharmazie und kosmetik
JP2003321352A (ja) 2002-04-24 2003-11-11 Nisshin Pharma Inc コエンザイムｑ１０含有組成物
JP2007084532A (ja) * 2005-08-24 2007-04-05 Kaneka Corp 分散性に優れた補酵素ｑ１０粉体
WO2007125915A1 (ja) * 2006-04-24 2007-11-08 Kaneka Corporation 補酵素ｑ含有固形物
AU2007261943B2 (en) * 2006-06-22 2012-11-01 Kaneka Corporation Reduced coenzyme Q10-containing composition and method for producing the same
KR100835250B1 (ko) 2006-09-07 2008-06-09 주식회사 바이오랜드 자기유화 전달체 및 이의 제조방법
EP2146692A1 (en) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
WO2009001787A1 (ja) * 2007-06-22 2008-12-31 Kaneka Corporation 補酵素ｑ１０含有組成物
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
WO2011046199A1 (ja) * 2009-10-16 2011-04-21 株式会社カネカ 還元型補酵素ｑ１０の製造方法、安定化方法及びそれを含有する組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004203812A (ja) * 2002-12-26 2004-07-22 Kanebo Ltd 経口組成物及びそれを有効成分とする美白剤
EP1591020A1 (en) * 2003-01-17 2005-11-02 Taiyo Kagaku Co., Ltd. Compositions containing coenzyme q10
JP2004242509A (ja) * 2003-02-10 2004-09-02 Nisshin Pharma Inc コエンザイムｑ１０およびアミノ酸類を含有する食品
US20070053985A1 (en) * 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2417970A4 *

Also Published As

Publication number Publication date
WO2010117199A2 (ko) 2010-10-14
KR101066197B1 (ko) 2011-09-20
CN102438606A (zh) 2012-05-02
JP5690809B2 (ja) 2015-03-25
EP2417970A2 (en) 2012-02-15
EP2417970A4 (en) 2012-10-10
KR20100111180A (ko) 2010-10-14
US20120041178A1 (en) 2012-02-16
US8785598B2 (en) 2014-07-22
CN102438606B (zh) 2014-06-18
EP2417970B1 (en) 2014-06-11
JP2012522835A (ja) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2010117199A3 (ko) 코엔자임 q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
WO2013041975A3 (en) Pyrethroid formulations
WO2008013785A3 (en) Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
WO2011081430A3 (ko) 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2013006729A3 (en) Cannabinoid receptor binding agents, compositions and methods
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2012106356A3 (en) Virus-like particles and methods of use
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
WO2012170889A8 (en) Cleavable lipids
ZA201100704B (en) Production,formulation,and uses of stable liquid harpin protein formulations
WO2010135589A3 (en) Dietary supplement drink for delivery of resveratrol and other polyphenols
WO2012009778A3 (en) A stable topical composition and a process for producing a stable topical composition
RS55900B1 (sr) Fermentisana mešavina na bazi soje koja obuhvata izoflavone-aglikone, equol i lunasil, postupak za pripremanje i njene upotrebe u prehrambenim, medicinskim i kozmetičkim oblastima
WO2007082155A3 (en) Molecules with complexing groups for aqueous nanoparticle dispersions and uses thereof
WO2012064126A3 (ko) 의료용 접착제 조성물
WO2012035283A8 (en) Pharmaceutical composition
WO2011121560A3 (en) Stabilized antibody preparations and uses thereof
EP1769843A3 (en) Use of 2,3-Dihydroxynaphthalene-6-Sulfonic Acid Salts as Dispersants
WO2011116220A3 (en) Oral supplement
WO2010116382A3 (en) Stable pharmaceutical compositions of diclofenac
WO2012040331A3 (en) Multistage nanoparticles
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
EP2709455A4 (en) PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080020168.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761860

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13263296

Country of ref document: US

Ref document number: 2012504607

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010761860

Country of ref document: EP